Bacteria are unwilling hosts to bacteriophages (phages), the dedicated viral pathogens that prey on them. In response to the assaults, bacteria and their prokaryote counterparts, the archaea, developed CRISPR/Cas systems (clustered regularly interspaced short palindromic repeats/CRISPR-associated proteins) to capture and store samples of the invader's DNA and use it to recognize and respond quickly and specifically to similar new infecting viruses.
"Phage are the most numerous and most diverse life forms on Earth, " says Merry Youle, author of Thinking Like a Phage: The Genius of the Viruses That Infect Bacteria and Archaea. "Every ecosystem rests upon vast numbers of phage and their infected prokaryote hosts which are the foundation of both ecology and evolution…. It's a bacterium's worse nightmare, the arrival of that one phage in a million who will evade all of its state-of-the-art defenses, who arrives with a plan of its own, speaks a language understood by cellular machinery, and knows how to divert the cell's energy and resources to virion production. "
Although researchers generally have believed that phages do not interact with eukaryotic cells, new studies led by Jeremy Barr, at Monash University in Melbourne, Australia, show otherwise. It appears that every day, an estimated 31 billion phage particles are transferred from the gut by epithelial cells into sterile body regions such as blood, lymph, and brain, where they help keep the sites bacteria free. Phages also bind to mucus at body openings, becoming a source of protection against incoming bacteria; in return, the phages get a steady supply of cellular virion factories.
Consequently, Barr concludes that "phage do interact with our cells, likely contributing to human health and immunity, " and act as "phageomes, " which are akin to friendly bacterial microbiomes.
To defend against phages, CRISPR/ Cas adaptive immunity operates in three main steps: memorize, load, and destroy. Early in the process, CRISPR/ Cas depends on a memorization complex to capture and integrate short pieces of the viral DNA into spacers in a part of the bacterium's genome called the CRISPR array. When activated, the spacer DNAs produce RNAs that are mirror images of phage DNAs and guide immune weapons to them. Research by Jennifer Doudna, at the University of California, Berkeley, and colleagues suggests that the molecular selectivity of the CRISPR could make it useful as a recording device for barcoding genomes among other purposes.
Notably, a "biological tape recorder" has recently been developed by Harris Wang and colleagues at Columbia University. Biological signals trigger DNA production that is recorded by the CRISPR/Cas system, and stable recordings over many days can be reconstructed by sequencing the DNA arrays. Biological tape can be used to record metabolic fluctuations and genetic changes in difficult-to-study habitats such as the mammalian gut or marine and soil environments.
Moreover, researchers so far have mostly used only the destroy function of the process for, for example, editing genomes. It seems that the functional potential of this amazing process has not yet been realized.
Thus, a process that has worked so well for bacteria for billions of years is being modified for other purposes and has already revolutionized gene editing, allowing scientists to manipulate a broad range of genomes quickly and rapidly. The ability of CRISPRs to work inside cells makes the approach even more valuable, write Rea Globus and Udi Qimron, at Tel Aviv University, in the September 2017 issue of Science.
Nonetheless, they suggest that future studies focus on the design of molecules that shed light on the next step of integration, during which single-stranded to double-stranded DNA takes place, and determine both the function and structure of the molecular steps leading to the sampling of invader DNA.
J. Jeffrey Morris, from the University of Alabama at Birmingham, notes that phages have long been used therapeutically to kill harmful bacteria. "When they were first discovered back in the 1920s, lots of people were working on this, but it fell out of favor with the discovery of penicillin, " says Morris. "Recently, though, as antibiotic resistance is spreading, researchers are taking a fresh look at phage therapy. Understanding how bad bacteria might use CRISPR/Cas to resist phages will be important to making phage therapy clinically useful. " Interestingly, intact phages may not always be necessary to gain benefits from these targeted antibacterial viruses. According to Cara Cassino, chief medical officer of Contrafect, a biotechnology company based in Yonkers, New York, an antistaphylococcal lysin, CF-301, secreted by phages, is now in its last stages of in vitro testing. CF-301 has proved synergic with conventional antibiotics providing "potent activity against current Staph aureus strains from infected patients in diverse geographies. "
